Ticker,Title,Link
SPRO,"TD Cowen ups Spero to buy, cites added clarity on catalyst timing",8/6/2024 7:53:59 PM
SPRO,Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update,8/5/2024 10:01:00 PM
SPRO,Here's what Wall Street expects from Spero Therapeutics's earnings,8/4/2024 3:01:13 PM
SPRO,"Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024",7/29/2024 10:05:16 PM
SPRO,3 Micro-Cap Moonshots for Fearless Investors,7/8/2024 7:07:22 PM
SPRO,Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4),7/3/2024 7:05:00 PM
SPRO,Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4),6/3/2024 10:05:00 PM
SPRO,Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference,5/16/2024 10:05:00 PM
SPRO,Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update,5/15/2024 10:05:37 PM
SPRO,Notable earnings after Wednesday's close,5/14/2024 9:35:24 PM
SPRO,"Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024",5/8/2024 2:00:00 PM
SPRO,Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),5/1/2024 10:07:35 PM
SPRO,Spero Therapeutics’ Robust Drug Pipeline and Positive Trial Advancements Prompt Buy Rating,3/18/2024 10:26:44 AM
SPRO,Spero Therapeutics files $300M mixed securities shelf,3/15/2024 8:45:20 PM
SPRO,Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session,3/14/2024 6:38:41 PM
SPRO,Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update,3/13/2024 9:01:00 PM
SPRO,Spero Therapeutics Q4 2023 Earnings Preview,3/12/2024 9:35:56 PM
SPRO,"Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024",3/6/2024 2:05:00 PM
SPRO,Spero Announces FDA Clearance Of IND Application For SPR206 ,2/28/2024 3:33:23 PM
SPRO,Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference,2/26/2024 2:05:00 PM
SPRO,Spero Therapeutics Announces Chief Legal Officer’s Resignation,2/10/2024 9:31:00 AM
SPRO,Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),1/31/2024 10:05:00 PM
SPRO,Spero Therapeutics Provides Corporate Update and 2024 Outlook,1/5/2024 2:05:00 PM
SPRO,Spero Therapeutics’ Promising Outlook: Clinical Milestones and Strategic GSK Partnership,1/3/2024 12:45:58 PM
SPRO,"Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections",1/2/2024 2:05:00 PM
SPRO,TD Cowen Keeps Their Hold Rating on Spero Therapeutics (SPRO),11/17/2023 7:25:37 PM
SPRO,"Analysts Offer Insights on Healthcare Companies: Durect (DRRX), Spero Therapeutics (SPRO) and eFFECTOR Therapeutics (EFTR)",11/14/2023 11:40:13 AM
SPRO,Here's what Wall Street expects from Spero Therapeutics's earnings report,11/12/2023 3:01:13 PM
SPRO,Buy Rating for Spero Therapeutics: Impact of New CFO and Imminent Phase 3 Trial Program,11/2/2023 6:53:38 PM
SPRO,Spero Therapeutics Appoints Esther Rajavelu CFO ,11/1/2023 2:24:48 PM
SPRO,4 Analysts Have This to Say About Spero Therapeutics,9/5/2023 9:00:16 PM
SPRO,HC Wainwright & Co. Maintains Buy Rating for Spero Therapeutics: Here's What You Need To Know,8/14/2023 7:00:30 PM
SPRO,"Spero Therapeutics GAAP EPS of -$0.23 beats by $0.11, revenue of $2.72M beats by $1.64M",8/10/2023 8:19:42 PM
SPRO,Spero Therapeutics Q2 2023 Earnings Preview,8/9/2023 9:35:41 PM
SPRO,H.C. Wainwright Reaffirms Their Buy Rating on Spero Therapeutics (SPRO),8/1/2023 10:25:16 AM
SPRO,Spero Therapeutics (SPRO) Receives a Buy from H.C. Wainwright,7/20/2023 10:15:17 AM
SPRO,"Spero Therapeutics GAAP EPS of -$0.25 beats by $0.08, revenue of $2.07M beats by $0.8M",5/11/2023 8:17:37 PM
SPRO,Notable earnings after Thursday's close,5/10/2023 9:35:55 PM
SPRO,H.C. Wainwright Sticks to Its Buy Rating for Spero Therapeutics (SPRO),4/10/2023 12:45:02 PM
SPRO,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday,3/31/2023 11:33:12 AM
SPRO,"Spero Therapeutics GAAP EPS of $0.55 beats by $0.51, revenue of $47.44M beats by $24.57M",3/30/2023 8:30:12 PM
SPRO,Notable earnings after Thursday's close,3/29/2023 9:35:59 PM
SPRO,Spero Therapeutics Q4 2022 Earnings Preview,3/12/2023 10:35:00 PM
SPRO,H.C. Wainwright Remains a Buy on Spero Therapeutics (SPRO),1/26/2023 11:15:17 AM
SPRO,"Spero Therapeutics GAAP EPS of -$0.33 misses by $0.03, revenue of $2M misses by $3.42M",11/14/2022 9:21:45 PM
SPRO,Spero Therapeutics Q3 2022 Earnings Preview,11/13/2022 10:35:31 PM
SPRO,Spero Therapeutics Q3 2022 Earnings Preview,11/11/2022 10:35:37 PM
SPRO,"EXCLUSIVE: Top 10 Stocks Searched On Benzinga Pro In September: Where Do Tesla, Apple, Bed Bath & Beyond Rank?",10/4/2022 8:29:12 PM
SPRO,"OMER, GLBE and QURE are among after hour movers",9/26/2022 9:10:41 PM
SPRO,Spero Therapeutics To Rally Around 240%? Plus This Analyst Slashes PT On Salesforce,9/23/2022 3:59:12 PM
SPRO,Dow Turns Higher; Crude Oil Rises 0.7%,9/22/2022 9:10:58 PM
SPRO,Why bluebird bio Is Trading Higher By Around 19%; Here Are 31 Stocks Moving Premarket,9/19/2022 12:53:49 PM
SPRO,"Terns, IVERIC top healthcare gainers; Alector, LifeStance lead losers' pack",9/9/2022 2:02:53 PM
SPRO,"PTN, ERAS  and Merc among mid-day movers",9/8/2022 4:54:38 PM
SPRO,"Why Korn Ferry Is Trading Lower By Over 8%, Here Are 40 Stocks Moving In Wednesday's Mid-Day Session",9/7/2022 6:22:21 PM
SPRO,Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate,9/6/2022 8:01:33 PM
SPRO,This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday,8/18/2022 10:59:45 AM
SPRO,"Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M",8/10/2022 8:50:44 PM
SPRO,"SPRO FINAL DEADLINE ALERT: ROSEN, A LEADING NATIONAL FIRM, Encourages Spero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRO",7/20/2022 8:00:00 PM
SPRO,"ROSEN, SKILLED INVESTOR COUNSEL, Encourages Spero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRO",7/14/2022 12:36:00 AM
SPRO,"SPRO INVESTOR NOTICE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Spero Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Ac...",7/4/2022 9:15:00 PM
SPRO,Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates,7/1/2022 11:26:23 AM
SPRO,LiveOne And 24 Stocks Moving Premarket,6/29/2022 12:32:23 PM
SPRO,"The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives",6/28/2022 3:11:23 PM
SPRO,FDA rejects Spero's application seeking approval of its urinary tract infection tablets,6/27/2022 8:13:53 PM
SPRO,"SPRO INVESTOR NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SPRO",6/21/2022 1:15:00 AM
SPRO,"ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Spero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRO",6/11/2022 7:12:00 PM
SPRO,"SPRO INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Spero Therapeutics, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action...",6/2/2022 11:43:00 PM
SPRO,Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates,5/31/2022 9:42:54 PM
SPRO,Biotech Stocks Facing FDA Decision In June 2022 ,5/27/2022 4:04:02 PM
SPRO,"Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2022",5/20/2022 4:02:44 PM
SPRO,Where Spero Therapeutics Stands With Analysts,5/17/2022 3:16:00 PM
SPRO,"Spero Therapeutics GAAP EPS of -$1.01 misses by $0.08, revenue of $2.07M beats by $0.14M",5/16/2022 8:09:46 PM
SPRO,Notable earnings after Monday's close,5/15/2022 9:35:38 PM
SPRO,"Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2022",5/4/2022 4:17:09 PM
SPRO,Mid-Afternoon Market Update: Kymera Therapeutics Drops After Q1 Results; Belite Bio Shares Spike Higher,5/3/2022 8:54:26 PM
SPRO,Spero Therapeutics stock dips after PT cut to $37 at H.C. Wainwright on pending approval of tebipenem HBr,4/18/2022 5:11:55 PM
SPRO,"ARRY, GOGO, ANGH and SPRO among after hour movers",4/5/2022 9:45:01 PM
SPRO,55 Biggest Movers From Friday,4/4/2022 10:59:20 AM
SPRO,38 Stocks Moving In Friday's Mid-Day Session,4/1/2022 6:56:24 PM
SPRO,"Spero Therapeutics GAAP EPS of -$0.90 misses by $0.15, revenue of $2.74M misses by $2.21M",3/31/2022 8:17:38 PM
SPRO,Notable earnings after Thursday's close,3/30/2022 9:35:24 PM
SPRO,"SPRO,AMTI and BRZE among after hour movers",3/29/2022 9:49:30 PM
SPRO,"The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck  Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More",3/27/2022 10:40:40 PM
SPRO,Spero Therapeutics antibiotic SPR206 shows promise in phase 1 trial,2/16/2022 2:06:09 PM
SPRO,Why Jim Cramer Like NextEra Energy And Lincoln Electric?,1/21/2022 1:58:37 PM
SPRO,Spero granted up to $12.9M by BARDA to develop urinary tract infection drug for children,1/19/2022 8:22:45 PM
SPRO,4 Stocks Insiders Are Buying,1/13/2022 1:17:41 PM
SPRO,FDA Lifts Clinical Hold On Spero Therapeutics' Lung Infection Program,1/4/2022 5:38:06 PM
SPRO,Spero's New Drug Application For Tebipenem HBr Tablets Granted Priority Review ,1/3/2022 2:56:13 PM
SPRO,"Spero Therapeutics EPS misses by $0.04, misses on revenue",11/10/2021 9:27:03 PM
SPRO,Notable earnings after Wednesday's close,11/9/2021 10:35:53 PM
SPRO,Spero Therapeutics submits tebipenem NDA for treatment of complicated urinary tract infections,10/28/2021 12:12:45 PM
SPRO,"The Past Week's Notable Insider Buys Included Asana, Designer Brands, Evergy And More",10/9/2021 5:20:17 PM
SPRO,3 Stocks Insiders Are Buying,10/5/2021 1:11:10 PM
SPRO,"Benzinga's Top Ratings Upgrades, Downgrades For October 1, 2021",10/1/2021 4:02:57 PM
SPRO,Spero Therapeutics Inks Revenue Interest Financing Agreement With HealthCare Royalty Partners,9/30/2021 9:00:46 PM
SPRO,4 Stocks Insiders Are Buying,9/2/2021 2:46:27 PM
SPRO,58 Biggest Movers From Friday,8/23/2021 11:06:17 AM
SPRO,"The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO",8/5/2021 2:07:56 PM
SPRO,What Wall Street expects from Spero Therapeutics's earnings,8/3/2021 3:02:13 PM
SPRO,"The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs",8/1/2021 4:13:48 PM
SPRO,"Everest Medicines: Spero Therapeutics, Pfizer In Deal For SPR206 In Ex-U.S. And Ex-Asia Territories ",7/5/2021 12:44:47 PM
SPRO,58 Biggest Movers From Yesterday,7/2/2021 11:08:22 AM
SPRO,30 Stocks Moving In Thursday's Mid-Day Session,7/1/2021 6:04:56 PM
SPRO,"Spero Therapeutics Kick Starts Two SPR206 Trials For Bronchoalveolar Lavage, Renal Impairment",6/16/2021 12:47:38 PM
SPRO,"The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO",5/18/2021 1:44:45 PM
SPRO,Spero Therapeutics awarded up to $23M funding by NIAID,5/17/2021 8:05:51 PM
SPRO,"The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom",5/6/2021 1:49:39 PM
SPRO,Spero Therapeutics is about to announce its earnings — here's what to expect,5/4/2021 3:02:12 PM
SPRO,"Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge",5/1/2021 7:19:25 PM
SPRO,"The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena",3/11/2021 2:19:03 PM
SPRO,Here's what Wall Street expects from Spero Therapeutics's earnings,3/9/2021 3:01:29 PM
SPRO,66 Stocks Moving In Friday's Mid-Day Session,2/5/2021 6:03:19 PM
SPRO,H.C. Wainwright boosts Spero Therapeutics price target on US patent for lead product,1/22/2021 8:33:10 PM
SPRO,Spero Therapeutics nabs US patent covering lead candidate,1/21/2021 7:52:20 PM
SPRO,Spero Therapeutics stock rises on agreement amendment with Everest Medicines II and its subsidiary,1/19/2021 6:29:41 PM
SPRO,"The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data",12/30/2020 2:08:28 PM
SPRO,"The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica",12/29/2020 2:09:37 PM
SPRO,Stocks That Hit 52-Week Highs On Monday,12/28/2020 4:22:20 PM
SPRO,"The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut",12/23/2020 2:30:53 PM
SPRO,61 Stocks Moving In Tuesday's Mid-Day Session,12/22/2020 6:43:32 PM
SPRO,Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer,12/17/2020 2:00:00 PM
SPRO,Spero Therapeutics Added to the NASDAQ Biotechnology Index,12/16/2020 2:30:00 PM
SPRO,Spero Therapeutics Announces First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease,12/10/2020 2:00:00 PM
SPRO,Spero Therapeutics Announces Appointment of Tamara Joseph as Chief Legal Officer,12/2/2020 2:30:00 PM
SPRO,Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),11/30/2020 11:01:08 PM
SPRO,Spero Therapeutics Announces Third Quarter 2020 Operating Results and Provides Business Update,11/5/2020 10:05:00 PM
SPRO,Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),11/3/2020 2:32:14 PM
SPRO,"Spero Therapeutics to Provide Business Update and Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020",10/29/2020 1:00:10 PM
SPRO,Spero Therapeutics to Present Data for All Pipeline Programs at IDWeek 2020,10/16/2020 2:30:10 PM
SPRO,Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),9/30/2020 10:59:24 PM
SPRO,Stock Alert: Spero Therapeutics Shares Up 17% ,9/29/2020 4:18:54 PM
SPRO,Spero Therapeutics Hosting Key Opinion Leader Call on Oral Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections,9/24/2020 2:30:10 PM
SPRO,Spero Therapeutics to Present at Investor Conferences in September,9/15/2020 2:00:10 PM
SPRO,Spero Therapeutics Announces Pricing of Securities Offering,9/11/2020 12:54:19 PM
SPRO,Spero Therapeutics Announces Proposed Public Offering,9/9/2020 10:33:25 PM
SPRO,Stock Alert: Spero Therapeutics Jumps 15% ,9/8/2020 5:07:10 PM
SPRO,Spero Therapeutics Announces FDA Acceptance of IND Application for SPR720,8/31/2020 2:00:10 PM
SPRO,Spero Therapeutics Announces Second Quarter 2020 Operating Results and Provides Business Update,8/6/2020 10:05:10 PM
SPRO,Here's what to expect from Spero Therapeutics's earnings,8/5/2020 3:04:13 PM
SPRO,Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),7/31/2020 11:04:15 PM
SPRO,"Spero Therapeutics to Provide Business Update and Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020",7/29/2020 10:01:10 PM
SPRO,Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),6/30/2020 11:19:23 PM
SPRO,Spero Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference,6/1/2020 2:15:10 PM
SPRO,What Wall Street expects from Spero Therapeutics's earnings,5/8/2020 3:01:40 PM
SPRO,Spero Therapeutics Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial (ADAPT-PO) of Oral Tebipenem HBr versus Intravenous Ertapenem for the Treatment of Complicated Urinary Tract Infection,5/5/2020 10:01:10 PM
SPRO,"Spero Therapeutics to Provide Business Update and Report First Quarter 2020 Financial Results on Friday, May 8, 2020",5/4/2020 2:00:10 PM
SPRO,Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),5/1/2020 12:59:13 AM
SPRO,Spero Announces Appointment of Scott Jackson to its Board of Directors,4/16/2020 2:30:10 PM
SPRO,Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),3/31/2020 10:45:10 PM
SPRO,Spero Therapeutics Announces Fourth Quarter and Full-Year 2019 Operating Results and Provides Pipeline Update,3/16/2020 1:45:00 PM
SPRO,Spero Therapeutics Receives FDA Orphan Drug Designation for SPR720 for the Treatment of Nontuberculous Mycobacterial (NTM) Infection,3/11/2020 1:30:00 PM
SPRO,Spero Therapeutics Announces Closing of Rights Offering,3/5/2020 10:01:00 PM
SPRO,Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2/28/2020 11:00:00 PM
SPRO,Spero Therapeutics to Present at March Investor Conferences,2/26/2020 10:00:00 PM
SPRO,Spero launches rights offering,2/11/2020 2:37:52 PM
SPRO,BARDA OKs additional funding for development of Spero antibiotic,2/5/2020 4:09:52 PM
SPRO,Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2/1/2020 12:54:38 AM
SPRO,Spero Therapeutics Announces Proposed Rights Offering,1/30/2020 2:00:00 PM
SPRO,Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense,1/13/2020 2:00:00 PM
SPRO,Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR720 and Announces Plans to Advance Program into Proof-of-Concept Clinical Trial in Patients with NTM Pulmonary Disease,12/4/2019 10:01:00 PM
SPRO,Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),11/29/2019 9:45:00 PM
SPRO,Spero Therapeutics to Host Key Opinion Leader Symposium in December,11/26/2019 2:30:10 PM
SPRO,Spero Therapeutics Announces Third Quarter 2019 Operating Results and Provides Pipeline Review,11/4/2019 10:05:00 PM
SPRO,Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),10/31/2019 10:08:26 PM
SPRO,Spero Therapeutics Announces Positive Recommendation to Continue Phase 3 Clinical Trial of SPR994 as Planned Following Independent Review Committee Analysis of SPR994 Treated Patients in Lead-in...,10/3/2019 2:00:00 PM
SPRO,Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),9/30/2019 11:00:00 PM
SPRO,Spero Therapeutics Announces Presentations at IDWeek 2019,9/26/2019 2:30:00 PM
SPRO,Spero Therapeutics Announces Second Quarter 2019 Operating Results and Provides Pipeline Update,8/8/2019 10:10:00 PM
SPRO,Spero Therapeutics Announces $5.9 Million Award from U.S. Department of Defense to Further Clinical Development of SPR206,7/16/2019 2:00:00 PM
SPRO,Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ,6/28/2019 11:00:00 PM
SPRO,Spero Therapeutics Announces Collaboration with Bill & Melinda Gates Medical Research Institute to Develop SPR720 for Tuberculosis,6/20/2019 2:00:00 PM
SPRO,Spero Therapeutics to Present Data for All Pipeline Programs at the ASM Microbe 2019 Conference,6/17/2019 2:30:00 PM
SPRO,Spero Announces $10 Million Registered Direct Offering of Common Stock,6/13/2019 2:00:00 PM
SPRO,Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),5/31/2019 11:00:00 PM
SPRO,Spero Therapeutics Announces First Quarter 2019 Operating Results and Provides Pipeline Review,5/9/2019 10:10:00 PM
SPRO,Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),5/1/2019 2:00:00 PM
SPRO,Spero Therapeutics Highlights SPR994 Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases,4/8/2019 2:30:00 PM
SPRO,Spero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis,3/29/2019 1:00:00 PM
SPRO,Spero Announces Appointment of Cynthia Smith to its Board of Directors,3/19/2019 1:00:00 PM
SPRO,Spero Therapeutics to Present at March Investor Conferences,3/1/2019 2:30:00 PM
SPRO,Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR720,2/26/2019 2:00:00 PM
SPRO,Spero Therapeutics Announces FDA Acceptance of IND Application for SPR994,2/4/2019 1:00:00 PM
SPRO,Spero Therapeutics Announces Initiation of SPR720 Phase 1 Clinical Trial,1/29/2019 2:00:00 PM
SPRO,"Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial",1/7/2019 10:01:00 PM
SPRO,Spero Therapeutics Announces Third Quarter 2018 Financial Results and Pipeline Overview,11/8/2018 10:10:00 PM
SPRO,Spero Therapeutics Announces Positive Results from SPR720 IND-Enabling Studies and Plans to Initiate a Phase 1 Trial,11/5/2018 2:00:00 PM
SPRO,"CRMD On Watch, SPRO On Track To Initiate Phase 3 Trial, BMRA's Sales Drop ",10/17/2018 3:40:07 AM
SPRO,Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR206,10/11/2018 2:00:00 PM
SPRO,Spero Announces Positive SPR994 Phase 1 SAD/MAD Final Results,9/27/2018 10:01:00 PM
SPRO,Spero Therapeutics Announces Presentations at IDWeek 2018,9/25/2018 10:01:00 PM
SPRO,Spero Therapeutics to Present at the Cantor Global Healthcare Conference in October,9/19/2018 2:00:00 PM
SPRO,10 Pharma Stocks To Watch This Month ,9/2/2018 5:13:15 PM
SPRO,Spero Therapeutics to Present New Data for SPR994 and SPR206 at ESCMID/ASM 2018 Conference,8/28/2018 2:00:00 PM
SPRO,"Spero Announces Appointment of John C. Pottage, Jr., MD to its Board of Directors",8/14/2018 2:00:00 PM
SPRO,"SPRO To Report Data In Q3, ITRM Takes Steady And SURE Steps, PBYI On Watch ",8/10/2018 10:38:45 AM
SPRO,Spero Therapeutics Announces Second Quarter 2018 Financial Results and Pipeline Overview,8/9/2018 10:10:00 PM
SPRO,"EOLS Slumps On Stock Offering, BLCM CFO To Exit, NVRO Trims Revenue Outlook ",7/17/2018 7:53:10 AM
SPRO,Spero Awarded up to $54 Million by BARDA and DTRA to Support SPR994 Development,7/16/2018 12:59:00 PM
SPRO,Spero Therapeutics Announces Pricing of Securities Offering,7/13/2018 2:10:58 AM
SPRO,"ISR Soars On FDA Nod For GammaTile, KMPH On Watch, Investors Believe In XLRN ",7/10/2018 8:39:24 AM
SPRO,Spero Therapeutics Announces Proposed Offering of Common Stock,7/9/2018 10:10:00 PM
SPRO,"CLBS Firing On All Cylinders, SLDB Gets Ignited, SRPT Walks The Talk, SRRK Rocks ",6/20/2018 2:39:40 AM
SPRO,Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018,6/6/2018 4:08:00 PM
SPRO,Spero Therapeutics to Present New Preclinical Data for SPR994 at ASM Microbe 2018,6/5/2018 2:00:00 PM
SPRO,Spero Therapeutics to Present at the Jefferies 2018 Healthcare Conference in June,6/1/2018 2:00:00 PM
SPRO,Spero Therapeutics Announces Positive Top-Line Data for Two Product Candidates from its Potentiator Platform,5/23/2018 2:00:00 PM
SPRO,"BLFS Q1 Revenue Up 61%, VRAY Garners Attention, AKCA Gets FDA Panel Nod ",5/11/2018 7:11:45 AM
SPRO,Spero Therapeutics Announces First Quarter 2018 Financial Results and Pipeline UpdateMultiple data readouts expected throughout 2018 and SPR994 Phase 3 initiation anticipated around year-end 2018,5/10/2018 10:05:00 PM
SPRO,Spero Therapeutics to Present at Bank of America Merrill Lynch Health Care Conference in May,5/1/2018 3:00:00 PM
SPRO,Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID),4/20/2018 4:17:00 PM
SPRO,"Spero Therapeutics Highlights SPR741 Phase 1 and Preclinical Data at the 28th European Congress of Clinical Microbiology and Infectious DiseasesEight presentations on SPR741 at ECCMID, collectively...",4/16/2018 2:00:00 PM
SPRO,"Spero Therapeutics Appoints Ian A. Critchley, Ph.D., as Head of Clinical MicrobiologyBuilding organization to support SPR994 in Phase 3 and beyond, and robust pipeline",4/12/2018 2:00:00 PM
SPRO,Spero Therapeutics Announces Fourth Quarter and Full Year 2017 Operating Results and Provides Pipeline UpdatePoised to transition SPR994 from Phase 1 to Phase 3 around year-end 2018,4/2/2018 10:10:00 PM
SPRO,Spero Therapeutics to Present at Upcoming Investor Conferences,3/22/2018 1:00:00 PM
SPRO,Spero Therapeutics to Present at March Investor Conferences,3/1/2018 2:00:00 PM
SPRO,Spero Announces Appointment of David P. Southwell to its Board of DirectorsBroad leadership and financial expertise adds to our board’s breadth of talent and background,2/1/2018 2:00:00 PM
SPRO,"Motif Bio PLC, Spero Therapeutics, Inc. and Vical Incorporated Join Antimicrobials Working Group",1/29/2018 4:17:00 PM
SPRO,"Spero Therapeutics Appoints David Melnick, M.D., as Chief Medical OfficerDr. Melnick to lead clinical team as Spero prepares to enter late-stage clinical trials",1/4/2018 1:30:00 PM
SPRO,BRIEF-Spero Therapeutics Q3 Loss Per Share $36.02 (SPRO),12/14/2017 10:47:04 PM
SPRO,"FLKS Shrinks, SCPH Awaits FDA Decision In June, CLSD Looking Ahead To PEACHTREE ",12/6/2017 4:20:48 AM
SPRO,"BEAT Upbeat, SYRS Gearing Up For ASH, Catalyst-Rich Year Ahead For ARGX ",12/1/2017 3:46:30 AM
SPRO,"SMMT To Report Data In Q1, PRTA Slumps, DBVT's Viaskin Value Realised ",11/21/2017 2:49:35 AM
SPRO,Spero Therapeutics Announces Underwriters’ Option Exercise,11/13/2017 1:00:00 PM
SPRO,Spero Therapeutics Announces Closing of Initial Public Offering,11/6/2017 10:01:00 PM
